Core Viewpoint - Ascentage Pharma has received regulatory clearance from the US FDA and EMA to conduct a global Phase III study of olverembatinib for treating newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), marking a significant advancement in its clinical development efforts [1][3]. Company Overview - Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer, with a strong pipeline that includes third-generation kinase inhibitors and Bcl-2 inhibitors [6][7]. Clinical Development - The POLARIS-1 trial is a global, multicenter, randomized controlled Phase III study aimed at evaluating the efficacy and safety of olverembatinib in combination with chemotherapy for newly diagnosed Ph+ ALL patients [2][3]. - The trial is designed to accelerate the registration process for olverembatinib, particularly in the US and European markets, with simultaneous patient enrollment across multiple countries [1][2]. Efficacy and Safety Data - Preliminary data from the POLARIS-1 study indicates that approximately 65% of treatment-naïve Ph+ ALL patients achieved minimal residual disease (MRD) negativity and molecular MRD-negative complete response (CR) after three treatment cycles, significantly outperforming other drugs in the same class [3]. - The combination therapy demonstrated a favorable safety profile, with a low incidence of manageable adverse events [3]. Market Context - Ph+ ALL accounts for 20%-30% of all adult acute lymphoblastic leukemia cases and is associated with high relapse rates and poor prognosis, particularly in elderly patients [3]. - Prior to the introduction of tyrosine kinase inhibitors (TKIs), the five-year overall survival rate for Ph+ ALL was less than 20%, highlighting the need for improved treatment options [3]. Strategic Partnerships - Ascentage Pharma has signed an exclusive option agreement with Takeda for olverembatinib, which could lead to Takeda licensing global rights for the drug outside of certain regions, enhancing its commercial potential [4].

Core Points - FormFactor, Inc. will participate in the 14th Annual NYC Summit investor conference on December 16, 2025, at Mastro's Steakhouse in New York [1] - The NYC Summit features a "round-robin" format allowing investors and analysts to engage with management teams from 15 participating companies [2][3] - Attendance is by invitation only, limited to accredited investors and publishing research analysts, with a registration deadline of December 10, 2025 [4] Company Overview - FormFactor, Inc. is a leading provider of test and measurement technologies throughout the integrated circuit (IC) life cycle, supporting semiconductor companies in optimizing device performance and yield knowledge [5]

Core Viewpoint - North America Niobium and Critical Minerals Corp. is initiating a non-brokered private placement to raise up to $1,000,000 through the issuance of flow-through common shares at a price of $1.45 per share, aimed at advancing exploration programs in Quebec [1][5]. Group 1: Offering Details - The company plans to issue up to 689,655 flow-through common shares at $1.45 each, with gross proceeds expected to reach $1,000,000 [1]. - Finders' fees of up to 7.0% of the gross proceeds will be paid to eligible finders, along with non-transferable finders' warrants equivalent to 7.0% of the FT Shares sold [2]. - The proceeds will be allocated to eligible Canadian exploration expenses in Quebec, specifically for flow-through critical mineral mining expenditures, with a commitment to incur these expenses by December 31, 2026 [3]. Group 2: Regulatory and Closing Conditions - The closing of the offering is contingent upon receiving necessary corporate and regulatory approvals, including from the Canadian Securities Exchange (CSE) [4]. - All securities issued will be subject to a statutory hold period of four months plus a day from the issuance date [4]. Group 3: Company Overview - North American Niobium and Critical Minerals Corp. focuses on the acquisition and development of precious, base, and critical mineral assets, with properties in British Columbia and Quebec [6]. - The Quebec properties enhance the company's exposure to rare earth elements, niobium, and nickel-copper occurrences, which are vital for energy and defense applications [6].

Core Viewpoint - Mawson Finland Limited has received overwhelming shareholder approval for its business combination with First Nordic Metals Corp, which involves the acquisition of all common shares of Mawson by First Nordic through a statutory plan of arrangement [1][2]. Group 1: Shareholder Approval - A total of 11,568,435 common shares were voted at the special meeting, representing 52.09% of the issued and outstanding shares, with 100% voting in favor of the arrangement [2]. Group 2: Arrangement Details - The arrangement will exchange all issued and outstanding common shares of Mawson for 1.7884 First Nordic common shares after a 4:1 consolidation of First Nordic's shares, or 7.1534 on a pre-consolidation basis for each Mawson share [4]. - Following the completion of the arrangement, Mawson will become a wholly-owned subsidiary of First Nordic [4]. Group 3: Next Steps - The arrangement is subject to final approval by the Ontario Superior Court of Justice, with a hearing scheduled for December 8, 2025, and the closing is expected around December 16, 2025 [3]. Group 4: Company Background - Mawson Finland Limited is focused on the acquisition and exploration of precious and base metal properties in Finland, primarily gold and cobalt, holding a 100% interest in the Rajapalot Gold-Cobalt Project [6].

Core Insights - Grupo Aeroportuario del Pacífico (GAP) reported a 3.5% increase in total terminal passenger traffic across its 12 Mexican airports in November 2025 compared to November 2024 [2] - The overall passenger traffic for the year-to-date (January to November) also showed a growth of 5.8% [3] Passenger Traffic Summary - **Total Terminal Passengers**: Increased from 2,954.7 thousand in November 2024 to 3,096.6 thousand in November 2025, marking a 4.8% rise [3] - **Guadalajara Airport**: Experienced a significant increase in passenger traffic, rising by 10.4% year-over-year for November [3] - **Puerto Vallarta Airport**: Noted a 7.0% increase in passenger traffic for November [3] - **Tijuana and Los Cabos Airports**: Reported slight decreases in passenger traffic of 1.0% and 4.1%, respectively [3] Domestic vs. International Passengers - **Domestic Passengers**: Total domestic passengers decreased by 10.8% in November 2025 compared to November 2024 [5] - **International Passengers**: Total international passengers decreased by 2.0% in November 2025 compared to November 2024 [6] Highlights and Operational Insights - **Seat Availability**: Increased by 6.8% in November 2025 compared to the same month in 2024 [9] - **Load Factors**: Decreased from 85.2% in November 2024 to 78.1% in November 2025 [9] - **Impact of Hurricane Melissa**: The hurricane significantly affected Montego Bay Airport, with a 73.4% decrease in passenger traffic due to operational disruptions and damage to tourism infrastructure [2][11][12] Company Overview - Grupo Aeroportuario del Pacífico operates 12 airports in Mexico's Pacific region, including major cities and tourist destinations [13][14]

Core Viewpoint - Optiva Inc. has received the final court approval for its arrangement with Qvantel Oy, with the transaction expected to close by the end of the year [1][2]. Group 1: Arrangement Details - The arrangement involves Qvantel Oy acquiring all issued and outstanding common shares of Optiva at a price of C$0.25 per share [2]. - Holders of the 9.75% senior secured payment-in-kind toggle notes will receive approximately 22.4% of the Purchaser Shares, US$25 million in secured notes, warrants for additional shares, and potential cash payments based on surplus conditions [2]. - The arrangement was overwhelmingly approved by Optiva's shareholders and noteholders during special meetings held on November 27, 2025 [2]. Group 2: Company Overview - Optiva Inc. is a provider of cloud-native, AI-powered revenue management software for the telecommunications industry, established in 1999 and listed on the Toronto Stock Exchange [4]. - The company's solutions aim to help service providers capitalize on digital, 5G, IoT, and emerging market opportunities [4].

Fastest-growing educational technology leader replaces homegrown solution with authID to enable authentication, protect privacy, and prevent fraud for distance learning in complex environments DENVER, CO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- authID (Nasdaq: AUID), a leader in biometric identity authentication, today announced it was selected by an east coast-based innovative technology organization, serving the criminal justice sector, providing high quality education, reentry and rehabilitation resources for ...

This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024. ST. JOHN'S, Newfoundland and Labrador, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) has declared the following dividends payable on March 1, 2026 to the Shareholders of Record of the following Shares of the Corporation at the close o ...

Celebratory activities align with Faraday Future’s Middle East expansion and its vision for an intelligent electric mobility ecosystemDUBAI, United Arab Emirates, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“Faraday Future,” “FF,” or “the Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that, in connection with the United Arab Emirates’ 54th National Day, it showcased the FX Super One together with the ...

Core Insights - MEDIROM Healthcare Technologies Inc. has announced a distributor agreement with TD SYNNEX K.K. to enhance the distribution of its health-tech products, specifically the MOTHER Bracelet and REMONY system [2][3][4] Company Overview - MEDIROM MOTHER Labs Inc. is a subsidiary of MEDIROM Healthcare Technologies, focusing on health-tech solutions, including the development and sales of the MOTHER Bracelet and the REMONY health monitoring system [13] - The MOTHER Bracelet is a unique 24/7 recharge-free smart tracker that measures key health metrics such as heart rate, calories burned, body temperature, step count, and sleep without needing to be removed for charging [7][10] Partnership Initiatives - The collaboration with TD SYNNEX aims to leverage its extensive sales network and expertise in IT product distribution to accelerate the nationwide expansion of MEDIROM's health management solutions [3][4] - TD SYNNEX has a proven track record in the Japanese market for successfully distributing smart trackers, which will benefit the partnership [4] Product Features - The MOTHER Bracelet utilizes advanced technology to generate electricity from temperature differences, ensuring continuous operation without recharging [7] - The REMONY system integrates the MOTHER Bracelet with a dedicated gateway for real-time health monitoring and data synchronization, addressing common issues of data loss during device charging [10][12] - The system is customizable for various industries, including elder care and health monitoring for night shift workers, enhancing its applicability [12]